Table 3.
Associations Between Biomarkers Measured in the First 90 Days of Doxorubicin Treatment and Echocardiographic Outcomes 4 Years Later in 156 Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukemia
| Left Ventricular Characteristic | Mean Z Score | SE | P v 0 | P for Equal Means |
|---|---|---|---|---|
| Fractional shortening | ||||
| Increased cTnT* | −0.84 | 0.26 | .001 | |
| Normal cTnT | −0.91 | 0.20 | < .001 | .82 |
| Mass | ||||
| Increased cTnT | −1.36 | 0.19 | < .001 | |
| Normal cTnT | −0.68 | 0.14 | < .001 | .004 |
| End-diastolic dimension | ||||
| Increased cTnT | −0.34 | 0.25 | .17 | |
| Normal cTnT | −0.06 | 0.17 | .74 | .35 |
| End-systolic dimension | ||||
| Increased cTnT | 0.13 | 0.26 | .60 | |
| Normal cTnT | 0.37 | 0.18 | .04 | .46 |
| End-diastolic posterior wall thickness | ||||
| Increased cTnT | −1.51 | 0.24 | < .001 | |
| Normal cTnT | −0.74 | 0.17 | < .001 | .008 |
| Thickness-to-dimension ratio | ||||
| Increased cTnT | −1.14 | 0.26 | < .001 | |
| Normal cTnT | −0.52 | 0.18 | < .001 | .054 |
| Fractional shortening | ||||
| Increased NT-proBNP† | −0.70 | 0.17 | < .001 | |
| Normal NT-proBNP | −1.43 | 0.55 | .01 | .19 |
| Mass | ||||
| Increased NT-proBNP | −0.87 | 0.12 | < .001 | |
| Normal NT-proBNP | −0.37 | 0.49 | .44 | .33 |
| End-diastolic dimension | ||||
| Increased NT-proBNP | 0.02 | 0.12 | .85 | |
| Normal NT-proBNP | −0.69 | 0.65 | .29 | .27 |
| End-systolic dimension | ||||
| Increased NT-proBNP | 0.37 | 0.13 | .006 | |
| Normal NT-proBNP | 0.02 | 0.63 | .98 | .58 |
| End-diastolic posterior wall thickness | ||||
| Increased NT-proBNP | −1.02 | 0.15 | < .001 | |
| Normal NT-proBNP | −0.20 | 0.49 | .68 | .10 |
| Thickness-to-dimension ratio | ||||
| Increased NT-proBNP | −0.87 | 0.16 | < .001 | |
| Normal NT-proBNP | 0.32 | 0.44 | .47 | .01 |
| Fractional shortening | ||||
| Increased hsCRP‡ | −0.82 | 0.18 | < .001 | |
| Normal hsCRP | −0.60 | 0.47 | .20 | .67 |
| Mass | ||||
| Increased hsCRP | −0.85 | 0.12 | < .001 | |
| Normal hsCRP | −0.39 | 0.60 | .52 | .47 |
| End-diastolic dimension | ||||
| Increased hsCRP | −0.06 | 0.13 | .68 | |
| Normal hsCRP | −0.24 | 0.70 | .73 | .79 |
| End-systolic dimension | ||||
| Increased hsCRP | 0.35 | 0.15 | .019 | |
| Normal hsCRP | 0.05 | 0.62 | .93 | .64 |
| End-diastolic posterior wall thickness | ||||
| Increased hsCRP | −0.95 | 0.16 | < .001 | |
| Normal hsCRP | −0.57 | 0.51 | .27 | .48 |
| Thickness-to-dimension ratio | ||||
| Increased hsCRP | −0.78 | 0.16 | < .001 | |
| Normal hsCRP | −0.16 | 0.58 | .78 | .23 |
Abbreviations: cTnT, cardiac troponin T; hsCRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide.
*
Increased cTnT defined as > 0.01 ng/mL.
†
Increased NT-proBNP defined as ≥ 100 pg/mL in patients ≥ 1 year old and ≥ 150 pg/mL in patients < 1 year old.
‡
Increased hsCRP defined as ≥ 1.9 mg/L.